HomeCompareTTBXF vs JNJ

TTBXF vs JNJ: Dividend Comparison 2026

TTBXF yields 5.43% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TTBXF wins by $28.9K in total portfolio value
10 years
TTBXF
TTBXF
● Live price
5.43%
Share price
$1.97
Annual div
$0.11
5Y div CAGR
21.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.2K
Annual income
$9,663.11
Full TTBXF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TTBXF vs JNJ

📍 TTBXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTTBXFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TTBXF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TTBXF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TTBXF
Annual income on $10K today (after 15% tax)
$461.47/yr
After 10yr DRIP, annual income (after tax)
$8,213.64/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TTBXF beats the other by $4,227.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TTBXF + JNJ for your $10,000?

TTBXF: 50%JNJ: 50%
100% JNJ50/50100% TTBXF
Portfolio after 10yr
$44.7K
Annual income
$7,176.26/yr
Blended yield
16.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TTBXF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TTBXF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTTBXFJNJ
Forward yield5.43%2.13%
Annual dividend / share$0.11$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR21.6%28%
Portfolio after 10y$59.2K$30.3K
Annual income after 10y$9,663.11$4,689.40
Total dividends collected$33.4K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: TTBXF vs JNJ ($10,000, DRIP)

YearTTBXF PortfolioTTBXF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,360$660.18$10,592$272.30+$768.00TTBXF
2$13,008$852.31$11,289$357.73+$1.7KTTBXF
3$15,027$1,109.08$12,123$472.89+$2.9KTTBXF
4$17,535$1,456.11$13,141$629.86+$4.4KTTBXF
5$20,694$1,930.97$14,408$846.81+$6.3KTTBXF
6$24,732$2,589.71$16,021$1,151.60+$8.7KTTBXF
7$29,981$3,517.39$18,122$1,588.22+$11.9KTTBXF
8$36,925$4,845.65$20,930$2,228.20+$16.0KTTBXF
9$46,292$6,782.36$24,792$3,191.91+$21.5KTTBXF
10$59,196$9,663.11$30,274$4,689.40+$28.9KTTBXF

TTBXF vs JNJ: Complete Analysis 2026

TTBXFStock

Tritax Big Box REIT plc is the only listed vehicle dedicated to investing in very large logistics warehouse assets (Big Boxes) in the UK and is committed to delivering attractive and sustainable returns for shareholders. Investing in and actively managing existing built investments, land suitable for Big Box development and developments predominantly delivered through pre-let forward funded basis, the Company focuses on large, well-located, modern Big Box logistics assets, let to institutional-grade tenants on long-term leases (typically at least 12 years in length) with upward-only rent reviews and geographic and tenant diversification throughout the UK. The Company seeks to exploit the significant opportunity in this sub-sector of the UK logistics market owing to strong tenant demand and limited supply of Big Boxes. The Company is a real estate investment trust to which Part 12 of the UK Corporation Tax Act 2010 applies (REIT), is listed on the premium segment of the Official List of the UK Financial Conduct Authority and is a constituent of the FTSE 250, FTSE EPRA/NAREIT and MSCI indices.

Full TTBXF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TTBXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TTBXF vs SCHDTTBXF vs JEPITTBXF vs OTTBXF vs KOTTBXF vs MAINTTBXF vs ABBVTTBXF vs MRKTTBXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.